AstraZeneca PLC is offloading to China Medical System Holdings Ltd. (CMS) selected commercial rights to two of its mature cardiovascular products with combined annual sales of around $250m in the markets being transferred.
The deal marks a step by AstraZeneca to concentrate effort on its newer drugs in China, which is now not...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?